4.28

0.94% 0.04

Pre-market: 4.28

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $4.28, with a volume of 449.73K. It is up +0.94% in the last 24 hours and down -9.32% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$4.24

Open:

$4.24

24h Volume:

449.73K

Relative Volume:

0.52

Market Cap:

$198.17M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-1.609

EPS:

-2.66

Net Cash Flow:

$-78.56M

1W Performance:

+3.38%

1M Performance:

-9.32%

6M Performance:

-73.66%

1Y Performance:

-85.44%

1-Day Range:

$4.165

$4.40

1-Week Range:

$3.7258

$4.40

52-Week Range:

$3.7258

$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

227

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	4.28	198.17M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

Mar 13, 2025

Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 13, 2025

Mar 12, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com

Mar 12, 2025

Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World

Mar 11, 2025

Mar 10, 2025

4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com

Mar 10, 2025

4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks

Mar 10, 2025

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq

Mar 10, 2025

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire

Mar 10, 2025

FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Mar 10, 2025

Mar 09, 2025

Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 09, 2025

Mar 08, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Mar 08, 2025

Mar 07, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World

Mar 07, 2025

FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World

Mar 07, 2025

Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World

Mar 07, 2025

Mar 05, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World

Mar 05, 2025

Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025

Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex

Mar 04, 2025

4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance

Mar 04, 2025

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com

Mar 04, 2025

4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World

Mar 04, 2025

Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World

Mar 04, 2025

Mar 03, 2025

4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks

Mar 03, 2025

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga

Mar 03, 2025

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 03, 2025

Mar 02, 2025

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance UK

Mar 02, 2025

Mar 01, 2025

4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position - TipRanks

Mar 01, 2025

FDMT stock touches 52-week low at $4.4 amid sharp annual decline - Investing.com Australia

Mar 01, 2025

Feb 28, 2025

4D Molecular Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 28, 2025

4D Molecular Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 28, 2025

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Feb 28, 2025

4D Molecular Therapeutics Reports Positive Clinical Data for 4D-150 in Wet AMD and DME, Outlines Strategic Pipeline and Financial Position - Nasdaq

Feb 28, 2025

Can 4DMT's $505M Cash Runway and Promising Eye Disease Data Overcome Rising Losses? - StockTitan

Feb 28, 2025

Feb 27, 2025

Spotlight On February 2025's Promising Penny Stocks - Simply Wall St

Feb 27, 2025

4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025

Feb 25, 2025